Literature DB >> 33896663

Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.

Yotam Levin1, Noa Madar Balakirski2, Yoseph Caraco3, Eytan Ben-Ami4, Jacob Atsmon1, Hadar Marcus5.   

Abstract

Entities:  

Year:  2021        PMID： 33896663     DOI： 10.1016/j.vaccine.2021.04.017

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  4 in total

1.  Cost-utility-safety analysis of alternative intradermal versus classical intramuscular COVID-19 vaccination.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-04-15

2.  Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.

Authors:  Nawamin Pinpathomrat; Porntip Intapiboon; Purilap Seepathomnarong; Jomkwan Ongarj; Ratchanon Sophonmanee; Jariya Hengprakop; Smonrapat Surasombatpattana; Supattra Uppanisakorn; Surakameth Mahasirimongkol; Waritta Sawaengdee; Supaporn Phumiamorn; Sompong Sapsutthipas; Chanon Kongkamol; Thammasin Ingviya; Pasuree Sangsupawanich; Sarunyou Chusri
Journal:  NPJ Vaccines       Date:  2022-05-13       Impact factor: 9.399

3.  Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.

Authors:  Porntip Intapiboon; Purilap Seepathomnarong; Jomkwan Ongarj; Smonrapat Surasombatpattana; Supattra Uppanisakorn; Surakameth Mahasirimongkol; Waritta Sawaengdee; Supaporn Phumiamorn; Sompong Sapsutthipas; Pasuree Sangsupawanich; Sarunyou Chusri; Nawamin Pinpathomrat
Journal:  Vaccines (Basel)       Date:  2021-11-23

Review 4.  Viral vector and nucleic acid vaccines against COVID-19: A narrative review.

Authors:  Saeed Khoshnood; Roya Ghanavati; Maryam Shirani; Hossein Ghahramanpour; Mohammad Sholeh; Aref Shariati; Nourkhoda Sadeghifard; Mohsen Heidary
Journal:  Front Microbiol       Date:  2022-08-31       Impact factor: 6.064
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.